Senti Biosciences, Inc. (SNTI.US) opened more than 7% higher on Tuesday, trading at $2.54. The surge follows the company's updated Phase 1 SENTI-202 trial data for relapsed/refractory acute myeloid leukemia (R/R AML), demonstrating a 50% overall response rate (ORR) and 42% complete remission/partial hematologic recovery (CR/CRh). Notably, most responses were minimal residual disease-negative (MRD-Negative) with durable effects. The trial has also received Regenerative Medicine Advanced Therapy (RMAT) designation to advance into pivotal studies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments